Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Usana Health SciencesUSNA +3.67%67 Equity-to-Asset is 0.75 as of Jun. 2026, which is 4% above its 10-year median of 0.72. GuruFocus rates USNA with a GF Score™ of 67/100 and a GF Value™ of $35.63 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 2,012 Consumer Packaged Goods companies, Usana Health Sciences ranks better than 79.62% on this metric.
Usana Health Sciences (NYSE:USNA) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Usana Health Sciences Equity-to-Asset Related Terms
Usana Health Sciences Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Usana Health Sciences's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
USNA vs NATR, BYND, BGS: Equity-to-Asset Comparison
For the Packaged Foods subindustry, Usana Health Sciences's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Usana Health Sciences Equity-to-Asset vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Usana Health Sciences's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Usana Health Sciences's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Usana Health Sciences's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Usana Health Sciences (USNA) has a Equity-to-Asset of 0.75 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Usana Health Sciences and its competitors. This is near median its historical median of 0.72. Over the past decade, Usana Health Sciences' Equity-to-Asset has ranged from 0.67 to 0.81. According to the industry distribution chart, Usana Health Sciences ranks #410 out of 2012 companies in the Consumer Packaged Goods industry, placing it in the top 20.4%.
Is Usana Health Sciences' Equity-to-Asset too high?
Usana Health Sciences' current Equity-to-Asset of 0.75 is near median its 10-year median of 0.72. Over the past 10 years, this metric has ranged from a low of 0.67 to a high of 0.81. The Consumer Packaged Goods industry median Equity-to-Asset is 0.55. Usana Health Sciences' value of 0.75 is 36.4% above this industry median. Based on the distribution chart, Usana Health Sciences ranks #410 out of 2012 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, Usana Health Sciences has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Usana Health Sciences' Equity-to-Asset compare to NATR and BYND?
According to the Consumer Packaged Goods industry distribution chart, Usana Health Sciences ranks #410 out of 2012 companies for Equity-to-Asset. This places Usana Health Sciences in the top 20% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.55. Usana Health Sciences' value of 0.75 is 36.4% above this benchmark. Historically, Usana Health Sciences' own Equity-to-Asset has ranged from 0.67 to 0.81 over the past decade. While the company's 10-year median is 0.72 vs. the industry median of 0.55, Usana Health Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Consumer Packaged Goods company?
The median Equity-to-Asset among Consumer Packaged Goods companies is 0.55, based on 2,012 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Usana Health Sciences's current Equity-to-Asset of 0.75 is 36.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Usana Health Sciences and its competitors. For the Consumer Packaged Goods industry, the median Equity-to-Asset is 0.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Usana Health Sciences's current Equity-to-Asset is 0.75, which is near median its own 10-year median of 0.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Usana Health Sciences stock overvalued right now?
Based on GuruFocus' analysis, Usana Health Sciences (USNA) is currently considered Possible Value Trap. The stock's GF Value™ is $35.63, compared to a current price of $14.96 — trading 58% below its estimated fair value. The current Equity-to-Asset is 0.75, which is near median its 10-year median of 0.72 and 36.4% above the Consumer Packaged Goods industry median of 0.55. Usana Health Sciences' overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Usana Health Sciences (USNA), the current Equity-to-Asset is 0.75 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Usana Health Sciences (USNA) Overvalued in 2026?
Based on GuruFocus' analysis, Usana Health Sciences stock appears to be undervalued.
The current stock price of $14.96 is trading 58% below its estimated GF Value™ of $35.63.
GuruFocus considers Usana Health Sciences to be Possible Value Trap.
Key valuation signals for USNA:
Equity-to-Asset: 0.75 (near median its 10-year median of 0.72)
GF Value™: $35.63 vs. price of $14.96 (58% below fair value)
Industry Position: 36.4% above the Consumer Packaged Goods median (#410 of 2012)
No single metric tells the full story. See the USNA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Usana Health Sciences Inc develops and manufactures high-quality nutritional supplements, functional foods, and personal care products that are sold throughout the world. The company has developed and manufactured high-quality, science-based nutritional, personal care, and skincare products with a primary focus on promoting long-term health and wellness. The Company's reporting units for goodwill purposes are tied to its reportable segments: Core nutritional and Hiya direct-to-consumer. The core nutritional segment consists of three individual reporting units that are determined based on the operational nature of the business: Buy-Sell, China, and India. Geographically, it is in Asia Pacific, the Americas, and Europe. With the majority of revenue from Asia Pacific(Greater China).
67GF Score
Get the complete analysis for USNA
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
USNA has been successfully added to your 
